Type 2 Diabetes and Cancer: What Is the Connection?
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Epidemiological studies have demonstrated an association between type 2 diabetes and cancer. Type 2 diabetes is characterized by insulin resistance and hyperinsulinemia. Hyperinsulinemia may lead to cancer through insulin's effect on its cognate receptor and the insulin‐like growth factor system. The effects of insulin and insulin‐like growth factor I on cancer development and progression have been demonstrated in animal and human studies. Type 2 diabetes has been positively associated with cancers of the breast, colon, and pancreas. An inverse relationship has been observed between type 2 diabetes and prostate cancer, and this may be due to lower testosterone levels in men with type 2 diabetes. Medications used to treat type 2 diabetes may affect cancer cells directly or indirectly by affecting serum insulin levels. Hyperinsulinemia may be an important risk factor for cancer as well as a target for cancer therapy. Mt Sinai J Med 77:197–213, 2010. © 2010 Mount Sinai School of Medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin Secretion
Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., & Nelson, D. A. (1995) · Science · doi:10.1126/science.7716547 · Cited by 1,315
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038
Cited by
White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Jane Henley, S. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2013.10.029 · Cited by 762
Identification of type 2 diabetes subgroups through topological analysis of patient similarity
Li, L., Cheng, W.-Y., Glicksberg, B. S., Gottesman, O., Tamler, R., Chen, R., Bottinger, E. P., & Dudley, J. T. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa9364 · Cited by 549
Diabetes and breast cancer risk: A meta-analysis
Boyle, P., Boniol, M., Koechlin, A., Robertson, C., Valentini, F., Coppens, K., Fairley, L.-L., Boniol, M., Zheng, T., Zhang, Y., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.414 · Cited by 358
“Insulin inhibits the production of sex hormone-binding globulin (Barker et al, 1964; Van der Burg et al, 1988), which results in an increase in free steroid hormones, free oestrogens in particular, because testosterone successfully competes with oestrogen for the sex hormonebinding globulin…”
BackgroundThe Link between the Metabolic Syndrome and Cancer
Braun, S., Bitton-Worms, K., & LeRoith, D. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.1003 · Cited by 326
Self-citationDiabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
“Diabetes and hyperglycemia are associated with an elevated risk of developing pancreatic, liver, colorectal, breast, bladder and endometrial cancer, and a lower risk of prostate cancer [3,4,46,47].”
BackgroundEnoyl-CoA hydratase-1 regulates mTOR signaling and apoptosis by sensing nutrients
Zhang, Y.-K., Qu, Y.-Y., Lin, Y., Wu, X.-H., Chen, H.-Z., Wang, X., Zhou, K.-Q., Wei, Y., Guo, F., Yao, C.-F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00489-5 · Cited by 68
“Protein-G-Agarose (16-266) was from Millipore, α-FLAG M2 Affinity Gel (A2200) was from Sigma-Aldrich.”
Systems and precision medicine approaches to diabetes heterogeneity: a Big Data perspective
Capobianco, E. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0155-4 · Cited by 39
“In general (see [15]) T2D presents two features associated with cancer: insulin resistance and hyperinsulinemia.”
BackgroundOthman, E. M., Oli, R. G., Arias-Loza, P.-A., Kreissl, M. C., & Stopper, H. (2016) · Endocrinology · doi:10.1210/en.2015-1572 · Cited by 23
“Hyperinsulinemia, an elevated insulin blood level characteristic of certain stages of diabetes, was investigated as possible reason for cancer development (11, 35).”
Background
Metadata
- Authors
- Cannata, D., Fierz, Y., Vijayakumar, A., & LeRoith, D.
- Venue
- Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Publisher
- Wiley
- Published
- 2010-03
- Volume
- 77
- Issue
- 2
- Pages
- 197-213
- ISSN
- 0027-2507 (ISSN-L)
- 1931-7581
- OpenAlex
- W1996610776
- Cited by
- 91
- References
- 27
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.